Omar Hussain 30 Year Proven Leadership in the Healthcare Data Security Industry Is Appointed to Secure AI Labs Board of Directors

November 24, 2020

Omar Hussain is the former CEO of Imprivata. The news was announced today by Secure AI Labs.

“Omar Hussain’s background in scaling Imprivata from a startup to IPO brings invaluable and relevant strategic expertise to the table. We are looking forward to his help in building out a scalable, secure, and efficient solution for hospitals to maintain patient data privacy while contributing to healthcare innovation,” said SAIL CEO Anne Kim.

“I am delighted to have been appointed to the Board of Directors at SAIL and look forward to working with the team to achieve business objectives,” said Hussain. “Privacy and compliance regulations have done a great job of protecting patient data, but have always been a challenge in providing secure access for critical medical research. SAIL’s unique approach to leveraging digital rights management and federated learning is an exciting opportunity that brings tremendous benefits to hospitals.”

Hussain brings over 30 years’ worth of proven leadership experience in the healthcare data security industry. An experienced CEO and business development advisor, Hussain’s expertise includes product strategy, marketing, operations management, investor relations, and customer onboarding and retention. As the CEO of Imprivata, Hussain drove exponential growth that led to IPO and over $160 million in annual revenue. In 2013, Hussain was named Ernst and Young’s “Entrepreneur of the Year” in New England’s security and compliance category.

Secure AI Labs offers hospitals the digital rights management platform to maintain full ownership and control of their data when conducting research, federated machine learning, and other analysis. Following SAIL’s investments from Argon Ventures, E14 Fund, Asset Management Ventures, Two Lantern Venture Partners, and Drive Catalyst, expanding the advisory team positions the MIT-born startup for continued growth.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."